First-in-Class Biologics for Regulating Energy Metabolism based on
Human Proteins with Novel Target and Mechanism
Mission
Transforming Disease and Suffering into Health and Happiness —
“A Company That Brings Warmth to the World”
Vision
To become a global R&D company that creates innovative biopharmaceutical technologies and healthcare services.
Core Values
Creativity
A pioneering spirit that drives creative innovation and value creation.
Humanism
A trusted company that respects life and advances human health.
Philanthropy
A commitment to social contribution and corporate responsibility.
CI Meaning
“The Smallest Molecular Engine regulating Energy Metabolism”
MEDI&GENE is a specialized R&D company focused on biopharmaceuticals and healthcare for metabolic diseases. Its name embodies the concept of a “Molecular Engine” — a continuous driving force for discovering novel targets and developing innovative molecular-level technologies to improve human health and happiness.
History
2026
01
Secured Series A Bridge Investment
2025
11
Signed a “Catalyze 360” Agreement with Eli Lilly
09
Expanded and relocated headquarters to the Korea University TechnoComplex Building
04
Selected for the MSS “Super Gap Startup 1000+” Program
2024
12
Selected for the MSS “Scale-up TIPS” Program under the SME Innovation R&D Project
06~10
Secured Series A Investment
2023
12
Signed an MTA with a Global Top-Tier Pharmaceutical Company
08
Relocated headquarters to Seoul BioHub
2022
08
Selected for the MSS “TIPS” Startup Commercialization Program
07~10
Secured Series A Investment
2021
11
Established the Corporate R&D Center, MEDI&GENE Bio-research institute
06
Founded MEDI&GENE Inc.